Goals of ProsTIC's theranostics research in prostate cancer

“We hope to further investigate next-generation PSMA-targeting molecules, develop new biomarkers to try to predict and monitor response to these novel therapies, optimize combinations with other treatments, and do some discovery research, including artificial intelligence [and] deep learning of our images,” says Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS.

Related Videos

Stephen J. Freedland, MD, on the benefits of mCRPC treatments translating to the real world

Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomy

Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC

Expert discusses the NMIBC trials landscape

John Gore, MD, on bladder preservation in muscle–invasive bladder cancer

Joy Maulik, CRNP, on the importance of genetic testing in prostate cancer

5 key trial insights from AUA 2025

Experts discuss expanding use of vibegron for OAB

John Michael DiBianco, MD, on silicone vs polyurethane stents for patients with kidney stones

Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC

Related Content

Advertisement

April 8th 2025

Baseline 68Ga-PSMA-11 PET/CT parameters can predict response to 177Lu-PSMA-617

Phillip Kuo, MD, PhD Hannah Clarke

"For every 1 unit increase in whole body tumor SUVmean, there was a 12% decrease in the risk of an rPFS event and a 10% decrease in the risk of death," says Phillip H. Kuo, MD, PhD, FACR.

June 22nd 2023

Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

Urology Times staff

"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.

March 31st 2025

18F-flotufolastat PET/CT shows high inter- and intrareader agreement rates

Phillip Kuo, MD, PhD

"I think a take-home message there is that in the prostate/prostate bed, you have to take extra time and caution in reading that region," says Phillip H. Kuo, MD, PhD.

March 27th 2025

Study finds geographic disparities in MRI use in prostate cancer

Hannah Clarke

The use of pre-diagnostic MRI was 3.8% in 2012, which increased to 32.6% in 2019.

March 20th 2025

FDA approves PET imaging product Gozellix for prostate cancer

Hannah Clarke

Gozellix – after radiolabeling with 68Ga – is indicated for PET imaging of PSMA positive lesions in men with prostate cancer who have suspected metastases and are candidates for initial definitive therapy and those who have suspected recurrence based on an elevated serum prostate-specific antigen level.

March 6th 2025

64Cu-SAR-bisPSMA shows efficacy in detection of biochemically recurrent prostate cancer

Hannah Clarke

The detection rate ranged from 44% to 58% on day 0 and 58% to 80% on day 1.

Related Content

Next-Generation Imaging

Next-Generation Imaging

Advertisement

April 8th 2025

Baseline 68Ga-PSMA-11 PET/CT parameters can predict response to 177Lu-PSMA-617

Phillip Kuo, MD, PhD Hannah Clarke

"For every 1 unit increase in whole body tumor SUVmean, there was a 12% decrease in the risk of an rPFS event and a 10% decrease in the risk of death," says Phillip H. Kuo, MD, PhD, FACR.

June 22nd 2023

Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

Urology Times staff

"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.

March 31st 2025

18F-flotufolastat PET/CT shows high inter- and intrareader agreement rates

Phillip Kuo, MD, PhD

"I think a take-home message there is that in the prostate/prostate bed, you have to take extra time and caution in reading that region," says Phillip H. Kuo, MD, PhD.

March 27th 2025

Study finds geographic disparities in MRI use in prostate cancer

Hannah Clarke

The use of pre-diagnostic MRI was 3.8% in 2012, which increased to 32.6% in 2019.

March 20th 2025

FDA approves PET imaging product Gozellix for prostate cancer

Hannah Clarke

Gozellix – after radiolabeling with 68Ga – is indicated for PET imaging of PSMA positive lesions in men with prostate cancer who have suspected metastases and are candidates for initial definitive therapy and those who have suspected recurrence based on an elevated serum prostate-specific antigen level.

March 6th 2025

64Cu-SAR-bisPSMA shows efficacy in detection of biochemically recurrent prostate cancer

Hannah Clarke

The detection rate ranged from 44% to 58% on day 0 and 58% to 80% on day 1.